In Vivo Assessment of Pharmacologic Vitreolysis in Rabbits With the Digital Fluoroscopy System
- PMID: 26218910
- DOI: 10.1167/iovs.14-16137
In Vivo Assessment of Pharmacologic Vitreolysis in Rabbits With the Digital Fluoroscopy System
Abstract
Purpose: The purpose of this study was to demonstrate the efficacy of the digital fluoroscopy system (DFS) for the in vivo assessment of pharmacologically induced posterior vitreous detachment (PVD) and vitreous liquefaction in a rabbit model.
Methods: Twenty eyes from 10 New Zealand white rabbits were divided into 5 groups. In each group, one rabbit received an intravitreal injection of 2.0 U plasmin in the right eye and 0.5 U plasmin in the left eye. Intravitreal injection of 0.1 mL balanced salt solution (BSS) was given in the right eye, and no injection was given in the left eye of another rabbit used as a control. Intraocular fluid dynamics were assessed by the DFS, using a contrast agent in each group at different time intervals (6 hours, 12 hours, 1 day, 3 days, and 7 days). After rabbits were killed, both eyes were enucleated. Scanning electron microscopy was used to confirm the morphological alterations of the vitreoretinal interface as observed in the DFS.
Results: Complete PVD was observed after 12 hours with 2.0 U plasmin injection, whereas complete PVD was observed only after 3 days in eyes injected with 0.5 U plasmin. Eyes that received BSS injection or did not receive an injection failed to show complete PVD even after 7 days. Complete vitreous liquefaction was observed after 7 days with 2.0 U plasmin injection, but no eyes with 0.5 U plasmin or BSS injection showed complete liquefaction. We could clearly confirm the presence of PVD and the degree of vitreous liquefaction by using DFS.
Conclusions: Digital fluoroscopy system appears to be a useful tool for the evaluation of pharmacological vitreolysis in rabbits with clear in vivo visualization of PVD and vitreous liquefaction.
Similar articles
-
PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy.Retina. 2005 Jan;25(1):38-43. doi: 10.1097/00006982-200501000-00005. Retina. 2005. PMID: 15655439
-
Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3295-9. doi: 10.1167/iovs.04-1517. Invest Ophthalmol Vis Sci. 2005. PMID: 16123432
-
[An experimental study on dissolving and detaching vitreoretinal interface with enzymes].Zhonghua Yan Ke Za Zhi. 2004 Jul;40(7):459-64. Zhonghua Yan Ke Za Zhi. 2004. PMID: 15454060 Chinese.
-
Pharmacologic vitreodynamics and molecular flux.Dev Ophthalmol. 2009;44:31-36. doi: 10.1159/000223943. Epub 2009 Jun 3. Dev Ophthalmol. 2009. PMID: 19494650 Review.
-
Pharmacologic vitreolysis in diabetic retinopathy.Curr Pharm Biotechnol. 2011 Mar 1;12(3):406-9. doi: 10.2174/138920111794480543. Curr Pharm Biotechnol. 2011. PMID: 20939804 Review.
Cited by
-
Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase.Mol Vis. 2021 Apr 1;27:125-141. eCollection 2021. Mol Vis. 2021. PMID: 33907368 Free PMC article.
-
Method for Quantitative Analysis of Vitreoretinal Adhesion in Ex Vivo Model.Transl Vis Sci Technol. 2024 Oct 1;13(10):3. doi: 10.1167/tvst.13.10.3. Transl Vis Sci Technol. 2024. PMID: 39352712 Free PMC article.
-
In Vivo Imaging of Intraocular Fluidics in Vitrectomized Swine Eyes Using a Digital Fluoroscopy System.J Ophthalmol. 2016;2016:9695165. doi: 10.1155/2016/9695165. Epub 2016 Apr 3. J Ophthalmol. 2016. PMID: 27127645 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources